Vera Therapeutics (VERA) said Wednesday that it would expand the development of its lead asset, atacicept, following positive results from the ongoing phase 2 and 3 trials in patients with IgA nephropathy and other autoimmune kidney indications.
The company said it plans to initiate a study in Q4 to give its ongoing phase 2 and 3 trials participants extended access to atacicept before it becomes commercially available, allowing for the collection of longer-term data.
It added that in 2025, the company plans to launch a study to assess atacicept's efficacy and safety in expanded IgAN populations, including adults with varying levels of kidney function and adolescents at high risk of progression.
The study will also extend to autoimmune glomerular diseases like primary membranous nephropathy and focal segmental glomerulosclerosis.
Price: 44.20, Change: +1.37, Percent Change: +3.20
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.